Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients

Background: Neprilysin inhibition has demonstrated impressive benefits in heart failure treatment, and is the current focus of interest in cardiovascular (CV) and kidney diseases. However, the role of circulating neprilysin as a biomarker for CV events is unclear in hemodialysis (HD) patients.Method...

Full description

Bibliographic Details

Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Hyeon Seok Hwang, Jin Sug Kim, Yang Gyun Kim, Yu Ho Lee, Dong-Young Lee, Shin Young Ahn, Ju-Young Moon, Sang-Ho Lee, Gang-Jee Ko, Kyung Hwan Jeong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Subjects:	cardiovascular disease hemodialysis neprilysin atherosclerosis left ventricular systolic dysfunction
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.684297/full